Development Of Guanylate Cyclase Activators For The Treatment Of Pulmonary Arterial Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$137,684.00
Summary
Pulmonary arterial hypertension (PAH) is a life threatening condition with few treatment options. It is marked by shortness of breath and reduced energy as a result of an unexplained constriction of the blood vessels in the lung. This results in reduced life expectancy. We are developing a new treatment that will relax the blood vessels in the lung to improve quality and length of life.
The Respire_ System: Portable Pulmonary Delivery Platform For Rapid, Flexible And Highly Efficient Treatment Of Elderly, Paediatric And Physically-Compromised Patients With Chronic Respiratory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$599,142.00
Summary
The development of a low-cost miniature drug delivery platform for the treatment of chronic respiratory diseases is proposed. The portable device has already been shown to be significantly more efficient than currently available asthma inhalers. In addition, the device offers the possibility of dose adjustment to account for patient variability, such as age and disease severity, as well as a reduction in patient intervention, thus making it more appropriate for patients unable to self-medicate.
Novel Soluble Guanylate Cyclase Activators For Pulmonary Artery Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$474,087.00
Summary
Pulmonary hypertension (elevated blood pressure in the lungs) is a life-threatening condition with few treatment options. We have recently identified a new class of drug that may improve blood vessel function in the lungs and thereby provide a new drug for the management of this group of patients.
Development Of Platelet-Targeted Nanoparticles For Magnetic Resonance Imaging Towards The Detection Of Thrombi/Emboli And Vulnerable Atherosclerotic Plaques
Funder
National Health and Medical Research Council
Funding Amount
$606,524.00
Summary
Heart attack, stroke and pulmonary embolism typically strike without warning and either kill patients or cause devastating disabilities. Currently, we do not have diagnostic methods to identify patients and the blood vessels at risk. We have developed a new innovative MRI nanoparticle directed against activated platelets for the detection of _at risk� blood vessels. The current funding is requested to optimise the manufacture of this targeted MRI nanoparticle and to undertake the animal studies ....Heart attack, stroke and pulmonary embolism typically strike without warning and either kill patients or cause devastating disabilities. Currently, we do not have diagnostic methods to identify patients and the blood vessels at risk. We have developed a new innovative MRI nanoparticle directed against activated platelets for the detection of _at risk� blood vessels. The current funding is requested to optimise the manufacture of this targeted MRI nanoparticle and to undertake the animal studies required to enter early stage clinical trials.Read moreRead less
Novel Single-chain Antibody-targeted Nanoparticles For Diagnosis Of Vascular Diseases In Magnetic Resonance Imaging
Funder
National Health and Medical Research Council
Funding Amount
$460,797.00
Summary
The aim of this project is to develop targeted imaging agents that seek out specific markers for various states of cardiovascular disease. These agents would provide a method for detecting the presence and level of atherosclerosis and thrombotic events. The targeted nanoparticles may provide a unique opportunity to detect very early plaques, the vulnerability of existing plaques and difficult to diagnose vessel blockages such as pulmonary embolism.
Development Of Resonance Energy Transfer Technologies To Detect GPCR Heterodimer Complexes In Living Cells
Funder
National Health and Medical Research Council
Funding Amount
$205,555.00
Summary
G-protein coupled receptors are proteins at the surface of most cells in the body. They bind to drugs, transmitting signals into cells that change what cells are doing. Recent research indicates that different types of these proteins can interact with each other and when one of these protein combinations binds a drug, it acts differently to when the proteins act separately. The aim of our project is to find out which protein combinations exist and to find drugs that bind to them specifically.